Nextferm Technologies Ltd. · TASE:NXFR.M
Nextferm Technologies — Investor Presentation (March 2023)
24 slides from Nextferm Technologies's investor presentation, March 2023
Slide 1: NextFerm Technologies: Leading the Alternative Protein Revolution
NEXTFERM TECHNOLOGIES Leading The Alternative Protein Revolution March 2022 TASE: NXFR
Slide 2: Disclaimer
This presentation is intended for the provision of non-comprehensive information for the sake of convenience solely. You are hereby referred to the full prospectus and immediate and periodic reports filed by the company with the Israel Securities Authority and the Tel Aviv Stock Exchange Ltd. for DI
Slide 3: About NextFerm: Leading the Alternative Protein Revolution
ABOUT NEXTFERM: LEADING THE ALTERNATIVE PROTEIN REVOLUTION Experienced Team in the Food and Food-tech Industry Breakthrough Technology for Innovative Yeast-based Proteins and Nutrients ProteVin™ Revolutionary Vegan Protein • Yeast Derived • Animal-like Nutritional Value • Neutral Flavor (unlike typi
Slide 4: ProteVin - Commercial Status
ProteVin™ - COMMERCIAL STATUS First launched - June 2022 Above 100 Companies 2 Launches in USA Above $3M POs & are evaluating ~16 Tons supplied Supply Agreement ProteVin™ 4
Slide 5: Launched in the USA by Spacemilk and Mushroom Design
Launched in the USA by Spacemilk and Mushroom Design Using ProteVin™ brand https://spacemilk.com/products/spacemilk-one-time https://mushroomdesign.com/products/mushroom-design-protein-powder 5
Slide 6: About NextFerm – The Team
ABOUT NEXTFERM – THE TEAM Experienced Team in the Food and Food-tech Industries Company management is comprised of former Senior Management of Enzymotec, which developed innovative ingredients within the world of nutrition. Enzymotec reached revenues of over $80M and went public (NASDAQ) during 2013
Slide 7: Experienced Management Team in the World of Nutrition
EXPERIENCED MANAGEMENT TEAM IN THE WORLD OF NUTRITION Yossi Ohana, CFO Boaz Noy, CEO and Director Yossi Peled, Chairman Former VP Finance of Enzymotec Former Sr. VP and Head of the BioActive Former Chairman and board member of Ingredients Division at Enzymotec Enzymotec and Former CEO of Galam Yoni
Slide 8: Breakthrough Technology
BREAKTHROUGH TECHNOLOGY FOR PRODUCING YEAST-DERIVED, INNOVATIVE, FUNCTIONAL VEGAN FOOD INGREDIENTS Yeast Improvement Fermentation Separation & Scale-up (Patented, Non-GMO) (Cost-effective) Purification (from Lab to Industry) Improvement of yeast Process optimization for Development of efficient Impl
Slide 9: The only fermented vegan protein with animal like nutritional value
The only fermented vegan protein with animal like nutritional value and neutral taste 9
Slide 10: Why Vegan Protein
THE WORLD GOES VEGAN DUE TO THREE REASONS: WHY Health Compassion Sustainability VEGAN Plant based diet is healthier Decrease animal suffering Securing world natural resources PROTEIN The growing shift towards vegan nutrition creates an increase in the need for vegan protein sources with better nutri
Slide 11: Alternative Finished Products Market Expected to Grow to $290B by 2035
ALTERNATIVE FINISHED PRODUCTS MARKET IS EXPECTED TO GROW TO $290B TILL 2035 (*) An Analysis by BCG and Blue Horizon : “Every Tenth Portion of Meat, Eggs, Dairy, and Seafood Eaten Around the Globe Will Be Made from Alternative Proteins by 2035” Expected alternative market growth 350 300 $290B (**) 25
Slide 12: Will Lead the Booming Vegan Protein Market
Will Lead The BOOMING Vegan Protein Market 12
Slide 13: ProteVin - Disruptive Value Proposition
PROTEVIN™- DISRUPTIVE VALUE PROPOSITION YEAST DERIVED NON-GMO VEGAN PROTEIN PRODUCED THROUGH INNOVATIVE FERMENTATION PROCESSES Animal-like nutritional value: • High level of Essential Amino Acids (53% EAA), Branched Amino Acids (21% BCAA) and 9% Leucine • Highly digestible protein (PDCAST=1) Neutral
Slide 14: The Leading Alternative Protein
Pea & Rice Protein Source ProteVin™ Whey Soy Blend Vegan Source + - + + Allergen Free / No impurities + - - - The leading + - - + alternative protein Sustainability Taste & Flavor + + + - Amino Acid Composition (AA) + + - - High Digestibility + + + - 14
Slide 15: Applications and Evaluation by Food Companies
Evaluation responds from food and dietary supplement Works great with companies, who are powders examining the integration of ProteVin™ in their products Works great with Works great with meat analogs Dairy substitutes Stable in Works great with sterilization fruits drinks process of up to 110C 15
Slide 16: ProteVin: Operational Plan
PROTEVIN™: OPERATIONAL PLAN 2023 H2 DEC DEC 2022 & 2022 2022 2024 Growth 1 Starting EU production A manufacturing agreement Commercial full-scale was signed with a production facility which subcontractor in North will lead the Company to Macedonia to establish a profitability production plant with a
Slide 17: ProteVin Key Goals for 2023
PROTEVIN™ 1. Establishing a production plant for ProteVin™ with a capacity of KEY GOALS 100s tons per year which will start a full-scale production during 2024; FOR 2023 2. Growing market demands & Additional orders for ProteVin™ in the US, Europe and other territories; 3. Industrial fermentation sc
Slide 18: Milestones & Target Markets
MILESTONES & TARGET MARKETS Key goals 2022 ProteVin™ market expansion to new segments and territories Commissioning of GFR (*) initial production line Dairy Infant Commercial Launch Well-being substitutes Nutrition Creating Demands Growth 1 project Sports’ Seniors’ Meat • ProteVin™ regulation IL Nut
Slide 19: Astaxanthin Yeast-Based Antioxidant
ASTAXANTHIN YEAST-BASED ANTIOXIDANT The only astaxanthin without taste or odor unlike alga based astaxanthin Offred as: • Gummies • Oil for soft-gels • Cold water dispersible powder Launched in USA & Canada 19
Slide 20: Patents and Regulation
PATENTS AND REGULATION NextFreeze™ Astaferm® ProteVin™ Patents EU: Granted for strain PCT filed for Strain Process patent was filed Russia: Granted for strain and for process composition Strain patent was filed Under evaluation in additional territories Open for marketing in US, EU and Regulation Op
Slide 21: Financial Information
FINANCIAL INFORMATION Cash & Cash equivalents as of December 31, 2022: ~ $3M The Cash will serve the company ongoing activities and production increase from tens to hundreds of tons per year Market B2C 2021 $36M Raised (2014-2023) Public Offering in the TASE (March 2023): Raised $5M Private Placemen
Slide 22: Financial Information
FINANCIAL INFORMATION USD in thousands 2022 2021 2020 STATEMENT OF OPERATION Net Revenues 262 242 95 Gross (Loss) Profit (**) (1,122) 23 19 Market Operating Loss (8,100) (4,467) (3,056) B2C 2021 Adjusted EBITDA (*) (7,275) (4,113) (2,635) BALANCE SHEET Cash, cash equivalents and Short term deposits
Slide 23: NextFerm - Summary
NextFerm - Summary Winning Alternative protein- Leading value proposition technology booming market in the global alternative platform protein market Experienced team Game changing a vegan protein with neutral taste & animal like nutritional value 23 23
Slide 24: Thank You!
THANK YOU! For more information: Yossio@nextferm.com www.nextferm.com
NextFerm Technologies — Investor Presentation (March 2023) on 6ix